Display options
Cite
Ciechomska IA, Marciniak MP, Jackl J, et al. Pre-treatment or Post-treatment of Human Glioma Cells With BIX01294, the Inhibitor of Histone Methyltransferase G9a, Sensitizes Cells to Temozolomide. Front Pharmacol. 2018;9:1271doi: 10.3389/fphar.2018.01271.
Ciechomska, I. A., Marciniak, M. P., Jackl, J., & Kaminska, B. (2018). Pre-treatment or Post-treatment of Human Glioma Cells With BIX01294, the Inhibitor of Histone Methyltransferase G9a, Sensitizes Cells to Temozolomide. Frontiers in pharmacology, 91271. https://doi.org/10.3389/fphar.2018.01271
Ciechomska, Iwona Anna, et al. "Pre-treatment or Post-treatment of Human Glioma Cells With BIX01294, the Inhibitor of Histone Methyltransferase G9a, Sensitizes Cells to Temozolomide." Frontiers in pharmacology vol. 9 (2018): 1271. doi: https://doi.org/10.3389/fphar.2018.01271
Ciechomska IA, Marciniak MP, Jackl J, Kaminska B. Pre-treatment or Post-treatment of Human Glioma Cells With BIX01294, the Inhibitor of Histone Methyltransferase G9a, Sensitizes Cells to Temozolomide. Front Pharmacol. 2018 Nov 02;9:1271. doi: 10.3389/fphar.2018.01271. eCollection 2018. PMID: 30450051; PMCID: PMC6224489.
Copy Download .nbib Format: NLM
Share it on

Front Pharmacol. 2018 Nov 02;9:1271. doi: 10.3389/fphar.2018.01271. eCollection 2018.

Pre-treatment or Post-treatment of Human Glioma Cells With BIX01294, the Inhibitor of Histone Methyltransferase G9a, Sensitizes Cells to Temozolomide.

Frontiers in pharmacology

Iwona Anna Ciechomska, Marta Patrycja Marciniak, Judyta Jackl, Bozena Kaminska

Affiliations

  1. Laboratory of Molecular Neurobiology, Neurobiology Center, Nencki Institute of Experimental Biology, Warsaw, Poland.

PMID: 30450051 PMCID: PMC6224489 DOI: 10.3389/fphar.2018.01271

Abstract

Glioblastoma (GBM) is a malignant, primary brain tumor, highly resistant to conventional therapies. Temozolomide (TMZ) is a first line therapeutic agent in GBM patients, however, survival of such patients is poor. High level of DNA repair protein, O

Keywords: BIX01294; glioma; histone methyltransferase G9a; sensitization therapy; temozolomide

References

  1. Mol Cell Biochem. 2014 Sep;394(1-2):23-30 - PubMed
  2. Nature. 2012 Aug 23;488(7412):522-6 - PubMed
  3. J Clin Oncol. 2008 Sep 1;26(25):4189-99 - PubMed
  4. Nat Rev Mol Cell Biol. 2007 Nov;8(11):931-7 - PubMed
  5. Int J Radiat Oncol Biol Phys. 2015 Aug 1;92(5):986-992 - PubMed
  6. J Clin Invest. 2012 Apr;122(4):1469-86 - PubMed
  7. Cell Death Differ. 2004 Apr;11(4):448-57 - PubMed
  8. CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 - PubMed
  9. Neurology. 2011 Sep 20;77(12):1156-64 - PubMed
  10. Mol Cell. 2007 Feb 9;25(3):473-81 - PubMed
  11. Biochim Biophys Acta. 2013 Dec;1833(12):3448-3459 - PubMed
  12. Eur J Cell Biol. 2013 Feb;92(2):70-9 - PubMed
  13. Int J Cancer. 2005 Apr 10;114(3):380-6 - PubMed
  14. Proc Natl Acad Sci U S A. 2012 Jan 17;109(3):841-6 - PubMed
  15. Mutat Res. 1997 Nov 28;381(2):227-41 - PubMed
  16. J Neurooncol. 2012 Mar;107(1):61-7 - PubMed
  17. Genes Dev. 2011 Apr 15;25(8):781-8 - PubMed
  18. J Cell Sci. 2004 Jun 1;117(Pt 13):2805-12 - PubMed
  19. J Biochem. 2005 Mar;137(3):431-40 - PubMed
  20. Front Immunol. 2015 Sep 25;6:487 - PubMed
  21. Expert Opin Investig Drugs. 2012 Sep;21(9):1391-415 - PubMed
  22. Sci Rep. 2016 Dec 09;6:38723 - PubMed
  23. Genes Dis. 2016 May 11;3(3):198-210 - PubMed
  24. Cell. 2007 Feb 23;128(4):693-705 - PubMed
  25. Mol Cancer. 2014 Jul 15;13:172 - PubMed
  26. Clin Cancer Res. 2008 Sep 1;14(17):5410-5 - PubMed
  27. J Biol Chem. 2001 Jul 6;276(27):25309-17 - PubMed
  28. N Engl J Med. 2005 Mar 10;352(10):987-96 - PubMed
  29. Pharmacol Rep. 2014 Feb;66(1):107-13 - PubMed
  30. Oncogene. 2013 Mar 21;32(12):1518-29 - PubMed
  31. Cancer Res. 2010 Oct 15;70(20):7830-40 - PubMed
  32. Oncotarget. 2017 Mar 7;8(10):16340-16355 - PubMed
  33. Lancet Oncol. 2009 May;10(5):459-66 - PubMed
  34. Mol Cell Biol. 2013 Oct;33(20):3983-93 - PubMed
  35. Nature. 2001 Nov 1;414(6859):105-11 - PubMed
  36. Brain Pathol. 1999 Jul;9(3):469-79 - PubMed
  37. Nature. 2006 Dec 7;444(7120):756-60 - PubMed
  38. J Clin Oncol Res. 2014 Jan 15;2(1):null - PubMed
  39. Cell Metab. 2013 Dec 3;18(6):896-907 - PubMed
  40. Curr Opin Cell Biol. 2010 Apr;22(2):226-33 - PubMed
  41. Mol Pharmacol. 1998 Aug;54(2):334-41 - PubMed
  42. Int J Cancer. 2005 Oct 20;117(1):59-67 - PubMed
  43. Oncol Lett. 2017 Mar;13(3):1767-1774 - PubMed
  44. J Biomed Biotechnol. 2012;2012:987495 - PubMed
  45. Cell Prolif. 2012 Aug;45(4):335-44 - PubMed
  46. J Biol Chem. 2010 Mar 26;285(13):9636-41 - PubMed
  47. J Neurooncol. 2007 Nov;85(2):159-70 - PubMed
  48. Pharmacol Res. 2018 Feb;128:252-263 - PubMed
  49. Neurochem Int. 2005 Nov;47(6):430-41 - PubMed

Publication Types